TEVA-RISEDRONATE TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE)

Prieinama:

TEVA CANADA LIMITED

ATC kodas:

M05BA07

INN (Tarptautinis Pavadinimas):

RISEDRONIC ACID

Dozė:

35MG

Vaisto forma:

TABLET

Sudėtis:

RISEDRONATE SODIUM (RISEDRONATE SODIUM MONOHYDRATE) 35MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

4/30

Recepto tipas:

Prescription

Gydymo sritis:

BONE RESORPTION INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0135301003; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2011-06-02

Prekės savybės

_ _
TEVA-RISEDRONATE
_ _
Page 1 of 54
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-RISEDRONATE
Risedronate sodium tablets
Tablets, 5 mg, 30 mg, 35 mg and 150 mg (as the monohydrate), Oral
Teva Standard
Bisphosphonates (ATC Code: M05BA07)
Teva Canada Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
October 10, 2013
Date of Revision:
April 18, 2023
Submission Control Number: 269246
_ _
TEVA-RISEDRONATE
_ _
Page 2 of 54
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
04/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
04/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
.......................................................................................................................
4
1.1
Pediatrics
....................................................................................................................
5
1.2
Geriatrics
.....................................................................................................................
5
2
CONTRAINDICATIONS
..........................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.........................................................................................
5
4.1
Dosing Considerations
.................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................. 5
4.4
Administration...................................